BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Verdino P, Atwell S, Demarest SJ. Emerging trends in bispecific antibody and scaffold protein therapeutics. Current Opinion in Chemical Engineering 2018;19:107-23. [DOI: 10.1016/j.coche.2018.01.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Klein C, Schaefer W, Regula JT, Dumontet C, Brinkmann U, Bacac M, Umaña P. Engineering therapeutic bispecific antibodies using CrossMab technology. Methods 2019;154:21-31. [PMID: 30453028 DOI: 10.1016/j.ymeth.2018.11.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
2 Nguyen AW, Maynard JA. Engineering Antibody‐Based Therapeutics: Progress and Opportunities. In: Zhao H, Lee SY, Nielsen J, Stephanopoulos G, editors. Protein Engineering. Wiley; 2021. pp. 317-51. [DOI: 10.1002/9783527815128.ch13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lim SI. Fine-tuning bispecific therapeutics. Pharmacol Ther 2020;212:107582. [PMID: 32450189 DOI: 10.1016/j.pharmthera.2020.107582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Wu X, Demarest SJ. Building blocks for bispecific and trispecific antibodies. Methods 2019;154:3-9. [PMID: 30172007 DOI: 10.1016/j.ymeth.2018.08.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]